RERG Inhibitors
Chemical inhibitors of RERG can target various components of the signaling pathways in which RERG is involved. Staurosporine, a broad-spectrum protein kinase inhibitor, can disrupt the phosphorylation events essential for RERG activity within the Ras signaling pathways. Similarly, LY294002 and Wortmannin, both phosphoinositide 3-kinases (PI3K) inhibitors, can impede the PI3K/Akt signaling pathway, which is known to interact with RERG, thereby reducing the activation of Akt and consequently RERG's functional activity. PD98059 and U0126, both MEK inhibitors, can prevent the activation of extracellular signal-regulated kinases (ERK), and since RERG functions downstream of this pathway, the inhibitors can effectively reduce RERG's signaling capacity. Additionally, SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), can abrogate JNK's role in stress-activated protein kinase pathways that interact with RERG's signaling mechanisms, directly hindering RERG's function.
In the same vein, SB203580, which selectively inhibits p38 MAP kinase, can disrupt the cross-talk between p38 MAP kinase and the Ras-related pathways where RERG operates, leading to an inhibition of RERG's functional role. Rapamycin, an mTOR inhibitor, can diminish the downstream effects of the PI3K/Akt pathway that involve RERG, thus directly inhibiting RERG's activity. GF109203X and Bisindolylmaleimide I are potent inhibitors of protein kinase C (PKC) and can impede signaling pathways upstream of RERG, thereby impairing RERG's functional signaling. PP2, as an inhibitor of Src family tyrosine kinases, can prevent the activity of Src kinases that are involved in the activation of RERG within various signaling pathways. Lastly, LY333531, which selectively inhibits beta isoforms of PKC, can inhibit the specific PKC isoforms that activate pathways including RERG, thus inhibiting RERG's activity within these pathways.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. RERG is involved in Ras signaling pathways, and kinase activity is pivotal in these pathways. Staurosporine inhibits these kinases, thus preventing the phosphorylation events necessary for the activation and function of RERG in signal transduction. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K). Since RERG is known to interact with the PI3K/Akt signaling pathway, inhibition of PI3K by LY294002 would lead to a reduction in Akt activation, thereby reducing the functional activity of RERG within this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK). MEK is upstream of extracellular signal-regulated kinases (ERK), which are involved in the Ras signaling pathway. Inhibition of MEK by PD98059 would inhibit ERK activation, thus inhibiting RERG's function in the signaling pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 works similarly to PD98059 by inhibiting MEK. Blocking MEK activity would prevent the downstream activation of ERK, a component of the signaling pathways in which RERG functions. As a result, RERG's role in these pathways would be inhibited. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor. By blocking PI3K activity, wortmannin would lead to a reduction in Akt activation. Since RERG interacts with the PI3K/Akt pathway, this inhibition would decrease RERG's functional activity within the pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK is involved in stress-activated protein kinase pathways, which can interact with Ras signaling pathways where RERG operates. Inhibition by SP600125 would prevent JNK's role in these pathways, thus inhibiting RERG's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. The p38 MAP kinase pathway is another signaling pathway that can cross-talk with Ras-related pathways involving RERG. Inhibition of p38 by SB203580 would disrupt this cross-talk, inhibiting RERG's functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mammalian target of rapamycin (mTOR), which is a component of the PI3K/Akt pathway. By inhibiting mTOR, rapamycin can decrease the downstream signaling that involves RERG, thereby inhibiting RERG's functional role in the pathway. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
GF109203X is a potent inhibitor of protein kinase C (PKC). PKC is involved in a myriad of signaling pathways, including those associated with Ras signaling. Inhibition of PKC by GF109203X would consequently inhibit RERG's function within these signaling pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. Src kinases are involved in various signaling pathways, including those associated with Ras signaling where RERG is active. Inhibition by PP2 would prevent Src kinase activity, thereby inhibiting the functional role of RERG in these pathways. | ||||||